`
`
`
`www.bloodjournal.orgFrom
`
`
`
`For personal use only.on September 29, 2015.
`
`CLINICAL
`
`PROFILES
`
`Intravenous
`
`fron-Dextran
`
`Complex
`
`By
`
`RALPH
`
`0. WALLERSTEIN
`
`W HEN
`
`widely
`in
`
`ficiency
`regard
`of
`oral
`injections.
`borhood
`regional
`iron
`in
`skin
`of
`
`an
`
`of
`reactions
`
`of
`
`became
`and
`
`of
`
`for
`the
`equally
`was
`consequent
`individual
`
`the
`of
`the
`the
`drug.
`
`COMPLEX
`IRON-DEXTRAN
`practical,
`effective,
`hailed
`as
`administered
`could
`be
`children.
`Iron
`in
`ability
`or willingness
`the
`patient’s
`or mother’s
`to
`could
`given
`in
`therapy.
`The
`total
`dose
`be
`The
`incidence
`untoward
`reactions
`was
`1 to
`1 per
`cent;
`included
`fever
`of
`iymphadenopathy.
`application
`drug
`Early
`deficiency
`anemia
`pregnancy
`during
`adults
`the
`larger
`requirement,
`dosage
`stains,
`the
`of
`volume
`and
`limitation
`trials
`of
`intravenous
`administration
`
`one
`
`it was
`1952
`available
`iron
`de-
`for
`safe
`therapy
`without
`doses
`adequate
`course
`a
`complete
`to
`four
`intramuscular
`to
`low,
`in
`the
`neigh-
`very
`3 days,
`arthralgia,
`and
`this
`to
`treatment
`of
`successful.
`However,
`local
`discomfort
`dose
`led
`to
`
`in
`
`and
`
`initiation
`
`Iron-dextran
`a special
`
`fraction
`
`complex
`of
`
`is
`dextran,
`
`a
`
`stable
`molecular
`
`preparation
`weight
`
`containing
`5,000
`
`to
`
`iron
`10,000.
`
`with
`complexed
`This
`low molec-
`
`PHARMACOLOGY
`
`weight
`contains
`tissue
`and
`
`dextran
`the
`fluids
`moves
`toxicity:
`the
`
`ular
`plex
`with
`charge
`very
`low
`determining
`total
`been
`pigs
`have
`than
`and,
`ical
`dose
`iron-dextran
`doses
`Large
`readings
`high
`false
`cause
`with
`not
`interfere
`does
`laboratory
`determinations,2
`
`appears
`equivalent
`and
`stable
`is
`to
`the
`anode
`is
`The
`LD50
`chronic
`toxicity
`given
`doses
`more
`year
`of
`
`to
`of
`
`act
`5 mg.
`in
`the
`on
`over
`of
`of
`later,
`complex
`serum
`of
`performance
`including
`
`as
`
`lyophilic
`a pH
`has
`of
`blood;
`
`of
`has
`it
`In mice
`iron/Kg.
`of
`
`protective
`a
`iron/mi.,
`presence
`electrophoresis.
`mg.
`1,000
`the
`preparation,
`as much
`as
`ill
`have
`shown
`serum
`color
`human
`low
`bilirubin,
`and
`results
`nor
`the
`typing
`crossmatching.3
`
`30
`
`mice,
`times
`no
`
`alter
`and
`
`com-
`colloid.
`isotonic
`6.5,
`and
`negative
`a weak
`the
`complex
`body
`weight.
`rats,
`and
`guinea
`equivalent
`chin-
`whatsoever.1
`This
`calcium,
`other
`standard
`
`The
`is
`
`has
`In
`
`may
`but
`
`the
`effects
`brown.
`serum
`of
`
`a
`
`the
`
`Hematology
`The Medical
`of Medicine.
`stsbmitted
`0.
`
`Research
`Service,
`
`Laboratory,
`San
`Francisco
`
`Children’s
`General
`
`Hos-pital
`Hospital,
`
`Adult
`and
`University
`
`Cen-
`Medical
`of
`California
`
`February
`
`WALLERSTEIN,
`
`8, 1968;
`M.D.
`
`accepted
`: Associate
`
`for
`
`publication
`Clinical
`
`April
`Professor
`
`1968.
`24,
`of Medicine,
`
`University
`
`From
`and
`ter,
`School
`First
`RALPH
`of California.
`
`690
`
`BLOOD,
`
`VOL.
`
`32, No.
`
`4 (Oc(cid:1)roBER),
`
`1968
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 1
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`From
`
`by guest
`www.bloodjournal.org
`
`
`
`
`For personal use only.on September 29, 2015.
`
`CLINICAL
`
`PROFILES
`
`691
`
`be
`
`and
`next
`had
`
`in
`
`body;
`the
`even
`milk,5
`slowly
`
`complex
`juice,
`serum.
`liver
`
`Iron-dextran
`gastric
`found
`in
`in
`high
`tration
`is
`the
`up
`by
`is
`taken
`available
`iron
`is made
`ance
`of
`radioactivity
`progressive
`a
`shows
`to
`the
`up
`that
`so
`less
`
`sacrum
`14
`days,
`to
`fallen
`iron-dextran
`
`seventh
`by
`the
`than
`the
`complex
`
`is
`
`day
`value.7’8
`of
`
`from
`excreted
`not
`is
`breast
`urine,4
`and
`stool,
`removed
`is
`complex
`The
`reticuloendothelial
`and
`the
`cells
`The
`formation.6
`hemoglobin
`for
`Surface
`days.
`2.5-3
`plasma
`is
`in
`over
`radioactivity
`in
`increase
`a gradual
`followed
`by
`day,
`radioactivity
`twenty-first
`the
`initial
`Viewed
`by
`composed
`aggregates
`of
`
`only
`when
`from
`tissues,
`half-time
`scintillation
`liver,
`
`the
`decrease
`over
`electron
`the
`closely
`packed
`
`the
`
`can
`traces
`concen-
`the
`blood
`and
`from
`which
`disappear-
`counting
`spleen,
`during
`the
`these
`sites
`microscope,
`spherical
`
`ferric
`presumably
`particles,
`material
`The
`same
`diameter.
`develops
`Ferritin
`injection.
`its
`by
`identified
`be
`can
`it
`synthesized
`apparently
`is
`It
`technics
`cannot
`histochemical
`of mothers
`treated
`Infants
`and
`hematologically
`normal
`are
`in maternal
`marrow.
`Studies
`iron
`keys
`treated
`iron-dextran
`1 / 2
`4
`per
`transferred
`iron
`is
`stored
`maternal
`red
`cells.8
`
`on
`
`is
`the
`
`with
`
`in
`
`cent,
`
`and
`complex
`across
`liver
`
`the
`
`and
`
`of
`a
`
`to
`
`measuring
`aggregates,
`hydroxide
`in
`reticuloendothelial
`seen
`can
`be
`ingestion
`proximity
`to
`the
`in
`close
`tetrahedron
`shape
`characteristic
`ferric
`hydroxide
`the
`from
`between
`these
`distinguish
`with
`iron-dextran
`complex
`do
`not
`have
`excessive
`fetal
`tissues
`show
`that
`placenta
`later
`appears
`
`micra
`1-3
`soon
`cells
`vacuoles,
`uniform
`
`after
`and
`size.
`Routine
`of
`iron.7
`pregnancy
`the
`iron
`in
`rhesus
`mon-
`portion,
`up
`to
`most
`of
`the
`maternal
`
`and
`aggregates.
`forms
`two
`in
`late
`amounts
`of
`pregnant
`small
`the
`fetus;
`in
`circulating
`
`iron
`
`Parenteral
`advantages
`its
`the
`treatment
`for
`of
`ministration
`
`over
`
`patients
`when
`case
`in
`the
`patients
`with
`
`a
`
`does
`
`raise
`
`INDICATIONS
`
`in
`
`levels
`not
`therapy
`tradional
`iron
`deficiency
`of
`iron-dextran
`complex
`relied
`cannot
`be
`upon
`clinic
`population;
`3)
`malabsorption
`syndromes
`
`to
`when
`
`of
`are
`the
`can
`take
`
`hemoglobin
`largely
`following
`replace
`iron
`iron
`
`faster
`technical.
`situations:
`avoid
`or
`medication
`absorption
`gastrectomy;
`
`is
`
`and
`
`after
`
`than
`It
`
`iron;
`oral
`indicated
`is
`1 ) when
`transfusions;
`orally
`as
`impaired,
`4)
`
`ad-
`2)
`
`often
`as
`
`in
`the
`
`is
`
`when
`
`form
`
`iron
`
`iron
`
`oral
`regional
`distress
`oral
`selves
`when
`repair
`
`of
`ileitis
`or
`change
`may
`gastrointestinal
`believed
`anemia
`is
`the
`iron
`deficiency
`
`Intravenous
`vantages.
`is more
`maintenance
`loss
`which
`bleeding
`
`administration
`therapeutic
`tolerated
`iron
`
`A full
`easily
`
`of
`cannot
`gastrointestinal
`
`be
`
`or
`
`well
`not
`is
`ulcerative
`of
`bowel
`accompany
`
`patients
`in
`tolerated,
`patients
`in
`colitis,
`of
`ingestion
`habits
`certain
`use
`of
`concurrent
`as
`chemotherapeutic
`such
`and
`than
`one
`cause,
`more
`have
`investigation
`is undertaken.
`further
`special
`iron-dextran
`complex
`has
`several
`of
`The
`can
`be
`in
`a
`single
`injection.
`dose
`injections
`individuals
`require
`repeated
`patients
`as
`in
`chronic
`gastrointestinal
`balance,
`surgically,
`congenital
`telangiectasia,
`repaired
`malignancies,
`some
`patients
`with
`
`irritants,
`to
`before
`
`in
`
`as
`
`and
`after
`
`given
`who
`
`with
`with
`in
`
`and
`
`with
`with
`the
`
`active
`nausea,
`drug.
`drugs
`
`ulcer,
`peptic
`abdominal
`Intolerance
`that
`are
`agents;
`it
`is
`
`them-
`and
`helpful
`
`to
`
`5)
`to
`
`ad-
`drug
`for
`blood
`with
`her-
`
`hiatus
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 2
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`by guest
`
`
`
`www.bloodjournal.orgFrom
`
`
`
`For personal use only.on September 29, 2015.
`
`692
`
`CLINICAL
`
`PI1OF(cid:1)LES
`
`It
`
`(cid:1)sritl(cid:1)
`
`or
`nias,
`examination.
`tients
`than
`patients
`with
`pura,
`because
`ously
`administered
`
`is
`
`does
`
`bleeding
`sites
`is
`better
`absorbed
`the
`intramuscular
`bleeding
`tendencies,
`intramuscular
`injections
`iron
`not.
`
`not
`
`detectable
`from
`injection.
`such
`
`even
`injection
`Finally,
`idiopathic
`cause
`
`the
`
`as
`can
`
`it
`
`after
`site
`is
`
`repeated
`in
`immobilized
`particularly
`thrombocytopenia
`hematomas,
`and
`
`radiologic
`
`useful
`
`pa-
`in
`pur-
`intraven-
`
`METHODS
`
`OF
`
`ADMINISTRATION
`
`In
`
`to
`fer
`syringe.
`
`general,
`two
`iron-dextran
`give
`Therapy
`is
`
`methods
`
`of
`complex
`initiated
`
`by
`
`administration
`undiluted.
`first
`giving
`
`have
`total
`ml.
`
`The
`1/2
`
`been
`dose
`The
`
`employed.
`is
`given
`needle
`
`a 2 minute
`
`wait
`
`for
`
`possible
`
`sensitivity
`
`reactions,
`
`then
`
`We
`a
`
`in
`left
`
`pre-
`single
`in
`the
`
`additional
`
`is
`
`an
`
`repeated
`are
`10 ml.
`injection.
`per
`injections,
`injections,
`This
`patients
`therapy,
`infusion
`
`have
`or who
`requiring
`
`a
`
`We
`or
`or with
`method
`of
`who
`
`iron.
`
`iron
`
`are
`
`given
`
`over
`
`ml.
`
`with
`
`vein
`4 1/2
`at
`convenient
`have
`not
`problem
`concomitant
`intravenous
`
`intervals,
`encountered
`with
`alternation
`oral
`and
`administration
`loss
`and
`and
`
`chronic
`are
`
`blood
`ambulatory
`
`3 minutes.
`next
`the
`or weekly,
`daily
`intolerance
`to
`of
`intramuscular
`intravenous
`is
`especially
`some
`form
`repeated
`
`of
`Injections
`allowing
`5 minutes
`repeated
`intravenous
`and
`intravenous
`administration
`of
`in
`useful
`treating
`of maintenance
`injections
`to
`
`a
`
`single
`
`need
`prefer
`
`5
`
`a
`in
`minute;
`
`utes
`
`to
`Other
`
`cent
`no
`
`per
`if
`40-60
`vehicles
`
`vol./vol.
`untoward
`drops/minute.
`for
`
`fused
`methods
`formly
`of
`2.5-7.5
`
`blood.
`of
`effective
`Gm.!
`
`to
`
`iron-dextran
`
`are
`
`5
`
`usually
`
`from
`
`cent
`per
`500-3000
`complex
`hemoglobin
`of
`amount
`or
`250 mg.
`or
`1.5 Gm.
`about
`250
`mg.
`below
`table
`
`is
`The
`
`stores.
`
`glucose
`mg.
`of
`intravenously
`rapidly,
`iron
`In
`
`in
`water
`elemental
`have
`at
`usually
`iron
`5 ml.
`in
`a 70 Kg. man
`of Hb
`per
`100
`of
`iron
`
`trans-
`or
`Both
`iron.
`uni-
`been
`rate
`the
`dextran
`this
`rep-
`ml.
`In
`each
`gram
`
`a
`
`for
`
`normal.
`of
`dosage
`
`This
`
`slight
`supplied
`
`ex-
`by
`
`hospitalization.
`
`The
`during
`and
`unlikely.
`
`method
`other
`pregnancy.
`other
`field
`The
`
`It
`situations
`indicated
`
`is
`has
`
`infusion
`also
`where
`vehicle
`
`the
`used
`
`of
`been
`more
`infusion
`
`for
`
`total
`
`in
`
`than
`
`of
`
`often
`
`is
`which
`dose,
`hookworm
`of
`cases
`doctor-patient
`one
`iron-dextran
`
`complex
`
`preferred
`infestation
`contact
`is
`
`was
`saline
`
`solution.
`effects
`
`Initially
`occur
`
`the
`
`is
`
`it
`rate
`
`at
`infused
`is
`increased
`
`a
`
`rate
`after
`
`of
`
`a
`
`20
`few
`
`drops!
`mm-
`
`vary
`Dosages
`iron-dextran
`administering
`of
`the
`level
`in
`raising
`100
`The
`3 weeks.
`in
`ml.
`blood
`1 pint
`of
`in
`that
`volume
`the
`blood
`cent
`of
`per
`10
`we
`administer
`average
`size
`of
`patient’s
`hemoglobin
`concentration
`adequate
`replacement
`of
`also
`be
`blood
`the
`
`equivalent
`is
`resents
`patient
`the
`that
`assures
`cess
`followed.
`may
`the manufacturer
`better
`is
`chronically,
`lose
`When
`patients
`with
`red
`cells
`labeling
`by
`radioiron
`lost
`iron
`with
`parenteral
`to
`replace
`attempt
`normal
`cannot
`reach
`patients
`but
`many
`because
`parenteral
`of
`iron,
`large
`amounts
`is mobilized
`for
`hemoglobin
`at which
`iron
`iron
`could
`accumulate
`in
`tissues
`despite
`
`can
`
`amounts
`also
`globin,
`
`ceive
`that
`of
`
`it
`
`to
`or
`according
`levels,
`rate
`their
`formation;
`chronic
`
`determine
`radiochromium.
`to
`levels
`though
`blood
`excessive
`anemia.
`
`even
`of
`
`the
`
`actual
`One
`hemo-
`of
`they
`re-
`exceeds
`amounts
`serum
`
`loss
`
`The
`
`the
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 3
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`From
`
`by guest
`www.bloodjournal.org
`
`
`
`
`For personal use only.on September 29, 2015.
`
`CLINICAL
`
`PHOF(cid:1)LES
`
`693
`
`Table
`
`1.-Reactions
`
`to Intravenous
`
`Iron
`
`Dextran
`
`Ant
`
`hon
`
`Number
`Cases
`Treated
`
`of
`
`Number
`Generalized
`
`of
`(cid:1) Reactions
`
`4.
`9.
`10.
`11.
`12.
`13.
`14.
`15.
`16.
`17.
`18.
`19.
`20.
`21.
`6.
`22.
`23.
`24.
`25.
`26.
`27.
`28.
`
`et
`
`al
`
`al.
`
`Marcha.sin
`Gartlan
`Varde
`Basu
`Clay et al.
`Dawson
`et
`Lane
`al.
`Smith
`Yoffa
`Bhatt
`Bonnar
`Hamstra
`Stohiman
`Thaman
`Will
`et
`Malcolm
`MaflSOfl
`(cid:1)Iaschas
`Pathak
`et
`Pate!
`Newcombe
`Ashby
`
`et
`
`et
`
`al.
`
`et
`
`al.
`
`al.
`
`al.
`
`et
`
`et
`a!.
`
`al.
`al.
`
`et
`et
`al.
`
`Total
`
`37
`55
`307
`30
`150
`133
`200
`18
`16
`75
`500
`225
`15
`106
`10
`12
`101
`47
`200
`45
`35
`
`._.?!
`
`2396
`
`1
`1
`1
`0
`7
`5
`1
`0
`0
`3
`5
`5
`1
`1
`0
`0
`2
`1
`0
`0
`0
`
`34
`
`*Does
`
`not
`
`include
`
`fever,
`
`lymphadenopathy,
`
`arthralgia.
`
`iron
`
`and
`
`total
`
`iron
`
`continues.
`obtain
`
`binding
`One
`deficiency
`meaningful
`iron
`to
`less
`useful
`is
`hemosiderin
`the
`reticuloendothelial
`
`ill
`
`capacity
`wait
`must
`serum
`because
`after
`
`cells
`
`checked
`be
`should
`after
`for
`3 weeks
`levels.
`Examination
`iron
`dextran
`some
`parenteral
`iron
`therapy.
`
`to
`
`the
`of
`usually
`
`verify
`latest
`the
`
`that
`injection
`marrow
`remains
`
`iron
`of
`for
`fixed
`
`UNTOWARD
`
`EFFECTS
`
`date
`
`has
`
`in
`
`over
`the
`been
`cent.
`
`To
`2,400
`world
`reported
`as
`low
`effects
`Most
`of
`per
`1-2
`a
`of
`test
`administration
`dyspnea,
`apprehension,
`photophobia,
`mation,
`may
`be
`tations
`( 1 day)
`arthralgia,
`apy
`occasionally
`to
`(trip,
`undiluted
`Despite
`
`has
`
`l)e more
`especially
`drug
`this
`
`patients
`literature
`as
`that
`the
`dose.
`cough,
`nausea,
`hypotension,
`lymphadenopathy,
`unmasked
`when
`common
`used
`when
`is administered.
`formidable
`
`treated
`(Table
`associated
`reactions
`Symptoms
`pain
`vomiting,
`cyanosis,
`
`latent
`material
`5 per
`
`the
`with
`
`with
`
`intravenous
`
`in
`
`dextran
`iron
`incidence
`The
`146928).
`intramuscular
`the
`with
`immediately,
`appeared
`include
`reported
`back,
`the
`chest,
`and
`bronchospasm.
`edema,
`erythema
`and
`local
`phlebitis.
`folic
`acid
`deficiency.11
`is
`diluted
`and
`given
`cent
`dextrose
`in
`
`water,
`
`been
`have
`untoward
`of
`route,
`about
`usually
`during
`flushing,
`headache,
`or
`abdomen,
`lacri-
`Other
`manifes-
`urticaria,
`delayed
`Iron-dextran
`ther-
`Phlebitis
`seems
`by
`intravenous
`than
`when
`
`the
`
`catalogue
`
`of
`
`symptoms,
`
`most
`
`of
`
`the
`
`reactions
`
`are
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 4
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`From
`
`694
`
`by guest For personal use only.on September 29, 2015.
`www.bloodjournal.org
`
`
`
`
`
`
`CLINICAL
`
`PROFILES
`
`of
`
`of
`
`The
`consistent
`agree
`
`transient
`and
`mild
`reported.
`been
`had
`no
`has
`observers
`All
`A rate
`occur
`was
`
`of
`
`50-100
`pregnant
`precipitated
`
`in
`
`not
`
`include
`and
`method
`relation
`the
`
`that
`mg.!minute
`women
`and
`
`no
`the
`
`did
`
`few
`a
`only
`administration
`to
`the
`type
`material
`must
`be
`should
`not
`special
`problems
`fetus
`not
`
`those
`or
`and
`not
`
`the
`the
`
`appear
`
`to
`
`listed;
`type
`of
`frequency
`administered
`be
`exceeded.
`When
`were
`encountered;
`be
`harmed.
`
`no
`
`fatalities
`
`have
`
`patient
`of
`too
`reactions
`i.e.,
`Iron
`
`treated
`reactions.
`rapidly:
`
`did
`labor
`over-
`
`load
`
`has
`
`not
`
`been
`
`a problem.
`
`SUMMARY
`
`in
`
`of
`
`observers
`by many
`Experience
`iron
`dextran
`administered
`venously
`anemia.
`iron-deficiency
`ment
`by
`the
`iron
`deficiency
`diagnosed
`values
`for
`the
`characteristic
`serum
`calculated
`inject
`well
`prefer
`to
`the
`the
`patient’s
`on
`capriciousness
`of
`the
`In
`clinical
`situations
`in which
`the
`
`last
`few
`the
`useful
`and
`is
`a
`conscientious
`The
`of
`hemosiderin
`absence
`total
`iron-binding
`and
`iron
`amount
`of
`iron
`correct
`gastrointestinal
`tract
`doctor-patient
`contacts
`
`years
`safe
`
`has
`agent
`physician,
`in marrow
`capacity,
`than
`rather
`or
`pill-taking
`are
`severely
`
`shown
`in
`
`the
`
`intra-
`that
`manage-
`who
`
`or
`
`has
`by
`may
`depend
`habits.
`limited
`
`injection
`iron.
`
`be
`
`to
`
`to
`
`in
`
`number,
`in
`proper
`the
`employing
`physician’s
`
`intravenous
`of
`amount
`diagnostic
`firm
`armamentarium
`
`may
`Treatment
`criteria,
`may
`and
`elevate
`
`the
`by
`restore
`from
`
`it
`
`reliable
`only
`intravenous
`iron
`buckshot
`
`its
`to
`
`way
`injection,
`proper
`bullet.
`
`administer
`only
`place
`
`after
`the
`
`SUMMARIO
`
`IN INTERLINGUA
`
`demonstrate
`ha
`annos
`passate
`curso
`le
`observatores
`numerose
`experientia
`in
`le
`thera-
`utile
`e salve
`mesura
`a ferro
`es
`de
`dextrano
`intravenose
`administration
`qui
`ferro.
`Le
`conscientiose
`a carentia
`de
`anemia
`carentia
`ha
`diagnosticate
`characteristic
`o
`base
`del
`de
`hemosideri.na
`in
`del
`absentia
`base
`a
`preferer
`va
`possibilemente
`le
`total
`capacitate
`ferro
`e
`pro
`pro
`seral
`gastro-
`capriciositate
`del
`a
`quantitate
`de
`ferro
`calculate
`le
`correcte
`su habitudes
`in
`ingerer
`del
`patiente
`o de
`que
`In
`situationes
`clinic
`de medico
`e patiente
`intra-
`br
`numeros,
`injection
`es
`fortemente
`restningite
`de
`administrar
`le
`appropriate
`le
`so!
`fidedigne
`maniera
`representa
`possibilemente
`post
`per
`injection
`intravenose-semper,
`sin
`dicer,
`de
`Le
`tractamento
`ferro.
`a
`su
`diagnostic-ha
`le
`potientalitate
`ferro
`stricte
`criterios
`de
`transformar
`su
`bombarda-
`de
`medico
`e
`armamentanio
`del
`ad
`attacco
`strategicamente
`precise.
`
`Le
`
`de
`
`in
`
`le
`
`que
`peutica
`de
`ferro
`valores
`injicer
`intestinal
`contactos
`venose
`quantitate
`le
`application
`le
`in
`juste
`rob
`mento
`indiscriminate
`
`de
`
`in un
`
`REFERENCES
`
`del
`un
`medico,
`le medulla
`ferro-ligatori,
`fiderse
`del
`pillulas.
`in
`
`a
`
`vias
`
`in
`
`le
`
`le
`
`de
`application
`
`il va
`restaurar
`ex
`
`un
`
`C. M.,
`Bates,
`J. D., McDonald,
`P.,
`London,
`pharmacology
`heamatinic.
`1955.
`M.
`and Wallenstein,
`
`E.,
`
`L.
`1. Martin,
`C. R., Donaldson,
`Dunlop,
`D.,
`Sheard,
`Twigg,
`C.
`D.:
`The
`iron-dextran
`intramuscular
`J. Pharmacol.
`10:375-82,
`J.,
`2. Brown,
`Sahud,
`R. 0.:
`Unpublished
`data.
`S. C.
`J.
`and Moss,
`3.
`Cox,
`dextran
`blood
`grouping.
`1:1299,
`
`and
`1966.
`
`G.
`Bnit.
`
`Iron-
`F.:
`Med.
`
`J.
`
`Beresford,
`S.
`
`E.
`
`of
`
`F.,
`and
`an
`Brit.
`
`4. Marchasin,
`treatment
`The
`intravenous
`with
`1964.
`354-358,
`5. Wallerstein,
`6. Richter,
`mation
`of
`into
`ferritin
`mental
`animals.
`1959.
`7. Will,
`
`C.
`
`S.
`of
`
`Wallerstein,
`and
`iron-deficiency
`iron
`dextran.
`
`0.:
`R.
`anemia
`Blood
`23:
`
`0.:
`R.
`The
`C. W.:
`colloid
`injected
`hemosidenin
`and
`J. Exp. Med.
`
`Unpublished
`cellular
`iron
`
`data.
`transfor-
`complexes
`in
`experi-
`109:197-216,
`
`and Groden,
`
`B. M.:
`
`The
`
`treat-
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 5
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`From
`
`by guest For personal use only.on September 29, 2015.
`www.bloodjournal.org
`
`
`
`
`
`
`CLINICAL
`
`PROFILES
`
`of
`
`deficiency
`A
`
`iron
`infusion:
`of
`papers).
`
`by
`
`anaemia
`radio-isotope
`J. Haemat.
`Brit.
`
`iron-
`study.
`14:
`
`J.
`N.:
`
`P.
`
`A. Milner
`F.
`metabolism
`of
`infusion
`total-dose
`subjects.
`Brit.
`
`and
`iron-
`to
`J.
`
`R.
`in
`
`R., Muir,
`of
`
`A.
`iron
`pregnant
`from
`a
`single
`intra-
`Brit
`dextran.
`
`Fe)
`
`ment
`dextran
`(Abstracts
`1968.
`61-71,
`K.,
`8. Wood,
`The
`U.
`Pathak,
`a
`as
`given
`dextran
`Jamaican
`deficient
`iron
`14:119-129,
`1968.
`Haemat.
`G.
`P. M.,
`Moss,
`Cotes,
`9.
`Scheuer,
`and
`J.:
`P.
`Distribution
`foetal
`maternal
`and
`tissues
`treated
`with
`monkeys
`rhesus
`of
`(59
`iron
`venous
`infusion
`J. Pharmacol.
`26(3):633-48,
`1966.
`J.: Parenteral
`C.
`10. Gartlan,
`J. 1:435,
`1964.
`nancy.
`Bnit.
`1 1. Varde,
`N.:
`Treatment
`of
`iron
`deficiency
`of
`of
`iron-dextran
`infllsiOfl
`Gyn.
`71:919-20,
`1964.
`of
`Administration
`S.
`12.
`Basu,
`K.:
`intravenous
`continuous
`dextran
`complex
`by
`J. Obstet.
`Gyn.
`72:253-258,
`1965.
`infusion.
`13.
`Clay,
`B., Rosenberg,
`B.,
`Sampson,
`N.
`Samuels,
`S.
`I. : Reactions
`to
`total
`dose
`and
`intravenous
`infusion
`of
`iron
`dextran
`(Im-
`J. 1(1):29-31,
`1965.
`feron). Brit. Med.
`0.
`W.
`14. Dawson,
`D. W.,
`Goldthorp,
`Spencer,
`and
`D.
`in
`therapy
`: Parenteral
`iron
`J. Obstet.
`1965.
`Gyn.
`72:89-93,
`pregnancy.
`J. M.:
`Reac-
`R.
`S.
`Scott,
`Lane,
`15.
`to intravenous
`dextran.
`Brit. Med.
`tions
`J. 1:449,
`1965.
`C.
`16.
`Smith,
`infusion
`technique.
`1965.
`“Imferon”-total
`17. Yoffa,
`Med.
`J. Aust.
`fusion
`technique.
`R. V.,
`Joshi,
`S. K.
`18.
`Bhatt,
`dose
`intravenous
`C.:
`Total
`M.
`(Imferon)
`iron-dextran
`in
`J. Obstet.
`Cynec.
`Amer.
`1966.
`19.
`
`Med.
`K.
`
`iron
`
`in preg-
`
`pregnancy
`complex.
`
`of
`by
`
`cases
`300
`dose
`total
`J. Obstet.
`
`iron
`
`and
`iron
`
`0.:
`
`“Imferon”-total
`J.
`Med.
`
`Aust.
`
`dose
`1:905,
`
`D.:
`
`in-
`1965.
`Shah,
`of
`
`dose
`11:51,
`and
`infusion
`anemia.
`severe
`94(8):1098-1102,
`
`Bonnar,
`obstetrics
`in
`infusion
`
`J.:
`
`of
`
`Rapid
`and
`iron
`
`correction
`gynecology
`dextran:
`
`of
`by
`A study
`
`ane-
`total
`of
`
`mia
`dose
`
`patients.
`of
`
`(Abstracts
`the mt. Soc.
`
`papers).
`of
`of Haemat.,
`
`695
`
`XIth
`Syd-
`
`M.
`R., Block,
`of
`intravenous
`(Abstracts
`the mt. Soc.
`of
`1966.
`J.,
`
`in
`
`Jr.
`: The
`treatment
`the
`papers).
`of
`of Haemat.
`
`and
`
`Newman,
`imferon
`papers).
`of
`of Haemat.,
`
`in
`
`intravenous
`of
`XIth
`Sydney,
`
`use
`de-
`iron
`Cong.
`Au-
`
`K. N.: Use
`and
`Dogra,
`P.
`0.
`iron-dextran
`in
`intravenous
`1965.
`11:412-414,
`N.:
`Iron-dextran
`infusion
`in
`disorder.
`Trans.
`60:245,
`1966.
`dosage
`I. W.:
`Total
`in pregnancy
`complex
`J. Aust.
`1 : 174,
`Med.
`M.
`al.:
`Traitment
`une
`par
`perfusion
`42(
`17):
`
`et
`graves
`fer
`Paris
`
`en
`
`de
`
`Hop.
`
`complex
`with
`Soc.
`
`anemia
`Roy.
`
`infusion
`and
`1966.
`des
`dose
`intra-
`1067-70,
`
`of
`
`500
`Congress
`ney,
`1966.
`20.
`Hamstra,
`M.:
`Investigation
`clinical
`medicine.
`XIth
`Congress
`Sydney,
`August
`21.
`Stohlman,
`iron-dextran
`of
`ficiency.
`(Abstracts
`of
`the
`Int.
`Soc.
`1966
`gust
`22.
`Thaman,
`of
`single-dose
`children.
`Lancet
`23.
`Malcolm,
`total
`dose
`by
`hepatosplenic
`Hyg.
`Trop.
`Med.
`24. Manson,
`with
`iron-dextran
`the
`puerperium.
`2.5. Maschas,
`amenies
`ferniprives
`unique
`et massive
`veineuse.
`Sem.
`1967.
`U. N., Wood,
`Pathak,
`26.
`of
`pregnancy
`: Anemia
`B. A.
`dose
`intravenous
`single
`29(4):500-507,
`Cynec.
`Obstet.
`K. M.
`and
`Tulloch,
`Patel,
`27.
`(iron-dextran
`imferon
`dose
`sion
`severe
`in
`therapy
`J. 2:605-607.
`Brit. Med.
`28.
`Newcombe,
`R.:
`travenous
`use
`J. 43:372-375,
`Med.
`29.
`Ashby,
`E. C.:
`fusion
`in
`general
`809,
`1967.
`C. W.,
`30.
`Heath,
`Quantitative
`Castle,
`W.
`hypochromlc
`in
`deficiency
`Invest. 11:1293-1312,
`
`J. K.,
`Sorhaindo,
`treated
`with
`iron-dextran.
`1967.
`J. A.: Total
`complex)
`infu-
`hookworm
`anaemia.
`1967.
`Precautions
`iron-dextran.
`1967.
`Total
`surgery.
`
`in-
`
`the
`in
`Postgrad.
`
`in-
`dextran
`11:807-
`
`iron
`Lancet
`
`Strauss,
`
`M.
`aspects
`anemia.
`
`and
`B.
`of
`iron
`J. Clin.
`
`1932.
`
`of
`
`B.:
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 6
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`by guest
`
`
`
`www.bloodjournal.orgFrom
`
`on September 29, 2015.
`
`For personal use only.
`
`1968(cid:160)32: 690-695
`
`LINICAL PROFILES
`
`(cid:160)C
`
`RALPH O. WALLERSTEIN
`
`Updated information and services can be found at:
`http://www.bloodjournal.org/content/32/4/690.full.html
`Articles on similar topics can be found in the following Blood collections
`
`Information about reproducing this article in parts or in its entirety may be found online at:
`http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
`
`Information about ordering reprints may be found online at:
`http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
`
`Information about subscriptions and ASH membership may be found online at:
`http://www.bloodjournal.org/site/subscriptions/index.xhtml
`
`Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of
`Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
`Copyright 2011 by The American Society of Hematology; all rights reserved.
`(cid:160)
`
`Luitpold Pharmaceuticals, Inc., Ex. 2014, p. 7
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01490
`
`(cid:160)(cid:160)
`(cid:160)